ArticleMolecular pharmaceutics2025
Machine Learning Modeling for ABC Transporter Efflux and Inhibition: Data Curation, Model Development, and New Compound Interaction Predictions.
Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ToxiVerse: chemical bioprofiling, toxicity data sharing and customizable predictive modeling.Bioinformatics (Oxford, England) · 2026Article
- Machine-Learning-Driven Optimization of Functional Excipients and Their Biointeractions in Drug Formulations.ACS pharmacology & translational science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In recent years, multiple computational studies have used machine learning models to predict substrate binding and inhibition of ATP-binding cassette (ABC) transporters. However, many of these studies relied on relatively small training sets with limited applicability. In this study, we manually curated over 24,000 bioactivity records (i.e., inhibition, binding affinity, permeability) for the ABC transporters P-gp, BCRP, MRP1, and MRP2 from more than 900 literature sources in ChEMBL, with additional data from PubChem and Metrabase. This effort yielded eight data sets, comprising around 8800 unique chemicals with one or more substrate binding or inhibition activities for these four efflux transporters. Quantitative structure-activity relationship (QSAR) models were developed for each of the eight data sets using combinations of four machine learning algorithms and three sets of chemical descriptors. The resulting models demonstrated excellent performance by 5-fold cross-validation, achieving an average correct classification rate (CCR) of 0.764 for the substrate binding models and 0.839 for the inhibition models. Models were validated with additional compounds from DrugBank that were known substrates or inhibitors. We further analyzed how model predictions for efflux transporter activity could estimate exposure of the brain to xenobiotics. Notably, compounds predicted as P-gp and BCRP substrates were twice or more likely to have low brain exposure compared to compounds with high brain exposure. This study provides a large and curated drug transporter binding and inhibition database for computational modeling. Applicable models based on this large database for predicting transporter substrate binding and inhibition can be used to evaluate more complex drug bioactivities, such as exposure of protected tissues to chemicals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.